Nurix recently unveiled their second clinical BTK degrader, NX-5948, which is in Ph. Ia/Ib for patients with advanced B-cell malignancies (NCT05131022). A novel CRBN ligand was developed to remove IKZF1/3 degradation activity, distinguishing NX-5948 from their earlier disclosed dual BTK-IKZF1/3 degrader NX-2127, which is currently in Ph. I for relapsed/refractory B-cell malignancies (NCT04830137). The potent BTK degrader NX-5948 has displayed CNS penetration preclinically, allowing for primary CNS lymphoma (PCNSL) participants to be included in the clinical study.
10 minute read
Oct. 11, 2023
The Highly Potent and CNS-Active NX-5948 Shows BTK Degradation in Patients
NX-5948
oral BTK degrader Ph. I for B-cell malignancies from degrader screening First Disclosures, ACS Fall 2023 Nurix Therapeutics, San Francisco, CA